Takeda Development Center Americas at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Takeda Development Center Americas at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Takeda Development Center Americas Cambridge, Massachusetts	1 presenter
takeda.com Subsidiary Takeda Development Center Americas conducts drug development and regulatory approval work for Takeda. Takeda develops treatments for patients. Won FDA approval for MIMRYLO, a new treatment for the blood disorder polycythemia vera, adding a hematology product. › Won FDA approval for MIMRYLO, a new treatment for the blood disorder polycythemia vera, adding a hematology product. 2026-08 · source Won FDA approval for ORZEYFUL, an oral drug for adult narcolepsy type 1, expanding its neurology portfolio. 2026-08 · source Made a reformulated version of its immunoglobulin therapy GAMMAGARD LIQUID ERC available in the US, expanding immunodeficiency treatment options. 2026-01 · source Source: company newsroom Parent Takeda Q1 FY2026 revenue ¥1.22T, up 10.2% › Guidance still calls for a low-single-digit core-revenue decline this year due to currency and exclusivity losses. · 2026-07-30 “Revenue \| 1,219.9 \| 1,106.7 \| +10.2% ... Revenue \| 4,640.0 \| — ... Core Revenue ... Low-single digit % decline” Source: results release Currently hiring: 357 open roles › Source: careers page	Poster Wed Oct 21 2:30 pm Part of Artificial Intelligence and Machine Learning Poster Wednesday Session Gene prioritization at GWAS loci using a retrieval-augmented literature mining framework Exhibit & Poster Hall · Board 8070W Artificial intelligenceBioinformaticsGenome-wide association studyIdentification of disease genes

Organization

ASHG 2026 Attendance

Takeda Development Center Americas

Cambridge, Massachusetts

1 presenter

takeda.com

Subsidiary

Takeda Development Center Americas conducts drug development and regulatory approval work for Takeda. Takeda develops treatments for patients.

Won FDA approval for MIMRYLO, a new treatment for the blood disorder polycythemia vera, adding a hematology product.

›

Won FDA approval for MIMRYLO, a new treatment for the blood disorder polycythemia vera, adding a hematology product.

2026-08 · source

Won FDA approval for ORZEYFUL, an oral drug for adult narcolepsy type 1, expanding its neurology portfolio.

2026-08 · source

Made a reformulated version of its immunoglobulin therapy GAMMAGARD LIQUID ERC available in the US, expanding immunodeficiency treatment options.

2026-01 · source

Source: company newsroom

Parent Takeda Q1 FY2026 revenue ¥1.22T, up 10.2%

›

Guidance still calls for a low-single-digit core-revenue decline this year due to currency and exclusivity losses. · 2026-07-30

“Revenue | 1,219.9 | 1,106.7 | +10.2% ... Revenue | 4,640.0 | — ... Core Revenue ... Low-single digit % decline”

Source: results release

Currently hiring: 357 open roles

›

Source: careers page

Poster

Wed Oct 21
2:30 pm

Part of Artificial Intelligence and Machine Learning Poster Wednesday Session

Gene prioritization at GWAS loci using a retrieval-augmented literature mining framework

Exhibit & Poster Hall · Board 8070W

Artificial intelligenceBioinformaticsGenome-wide association studyIdentification of disease genes

Instantly find 20 buyers from Takeda Development Center Americas

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction